Despite 60% Drop in Hepatitis B Treatment Efficacy, GSK Plans to Continue Trials
November 9th 2022Initially, 28-29% of patients with chronic hepatitis B achieved undetectable virus levels after 24 weeks of treatment with GSK’s bepirovirsen, but this dropped to 9-10% of patients during a phase 2b trial.
Wearing Masks Didn’t Increase Face Touching Among Kids in Simulated School Study
November 7th 2022The benefits to children of wearing face masks to prevent COVID-19 outweigh potential infectious risks from face touching, according to a study analyzing hand-to-face contact in a simulated school environment.
COVID-19 Vaccine Boosters: Roadblocks, the Future, and Communicating the Benefits to Patients
October 31st 2022“In the long run, what we will have is a virus that will become endemic in our population," said Donald J. Alcendor, MD. "The idea of thinking we can chase variants with boosters is a failed effort. We must realize that.”
The Next Generation of COVID-19 Vaccines and Boosters
Will there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?